Complete response to sunitinib for more than three years in a patient with a jejunum gastrointestinal stromal tumor: A case report

RATIONALE: Gastrointestinal stromal tumor (GIST) is the most common mesenchymal tumor of the gastrointestinal tract and is characterized by KIT mutations. Patientsresistant to 1st-line imatinib therapy are usually given sunitinib assecond-line treatment, which provides a median progression-free surv...

Descripción completa

Detalles Bibliográficos
Autores principales: Nie, Yanli, Sun, Wenjia, Xiao, Zhihua, Ye, Shengwei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6370167/
https://www.ncbi.nlm.nih.gov/pubmed/30653116
http://dx.doi.org/10.1097/MD.0000000000014060

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6370167/
https://www.ncbi.nlm.nih.gov/pubmed/30653116
http://dx.doi.org/10.1097/MD.0000000000014060

Ejemplares similares